Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
In patients with t(8;21) acute myeloid leukemia (AML), recurrent minimal residual disease (MRD) measured by RUNX1-RUNX1T1 transcript levels can predict relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to compare the efficacy of preemptive interferon (IFN...
Spremljeno u:
| Glavni autori: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2022-01-01
|
| Serija: | Frontiers in Oncology |
| Teme: | |
| Online pristup: | https://www.frontiersin.org/articles/10.3389/fonc.2021.773394/full |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
